Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO)

• Status: Unknown status
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to investigate whether intracoronary bolus administration of abciximab is superior to intravenous bolus administration in improving myocardial perfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Medical Center Groningen
• Treatments: Abciximab; Antibodies, Monoclonal; Immunoglobulin Fab Fragments

Criteria

Inclusion Criteria:

a diagnosis of STEMI defined by

• chest pain suggestive for myocardial ischemia for at least 30 minutes before hospital admission

• time from onset of symptoms of less than 12 hours

• ECG with ST-segment deviation of more than 0.1 mV in 2 or more leads

Exclusion Criteria:

• rescue PCI after thrombolytic therapy

• need for emergency coronary artery bypass grafting

• presence of cardiogenic shock

• known existence of a life-threatening disease with a life expectancy of less than 6 months

• inability to provide informed consent

• contra-indications for the use of abciximab (active internal bleeding, history of stroke within 2 years, recent major surgery or intracranial or intraspinal trauma or surgery within 2 months, intracranial neoplasm, arteriovenous malformation or aneurysm, bleeding diathesis, severe uncontrolled hypertension, thrombocytopenia, vasculitis, hypertensive or diabetic retinopathy, severe liver or kidney failure, and hypersensitivity to murine proteins)